Cisco Systems Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Cisco Systems Inc trades at $121.24 (market cap $483.10B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Cisco Systems Inc is far larger — about 5.8× Regeneron Pharmaceuticals Inc's market cap, and Cisco Systems Inc pays the higher dividend (1.37%). Which is the better fit depends on your goals.
| CSCO | REGN | |
|---|---|---|
Market Cap | $483.10B | $83.19B |
Volume | 22,887,319 | — |
Sector | Technology | Health |
52-Week High | $130.00 | $812.27 |
52-Week Low | $66.20 | $555.51 |
Enterprise Value | $497.76B | $77.90B |
Dividend Yield | 1.37% | 0.47% |
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $120.43, down 0.82% on the day, amid a bullish technical outlook and strong earnings beats. The stock shows robust fundamentals with a 64.33% gross margin and consistent quarterly EPS outperformance. Recent AI cybersecurity initiatives and partner expansions fuel positive sentiment, with a consensus price target of $133.25 implying upside potential.
The outlook remains favorable given AI-driven growth catalysts and solid cash flow, though elevated valuation ratios and competitive pressures pose risks. Analyst consensus leans bullish with 52% buy ratings, supporting a constructive view for investors seeking exposure to networking and cybersecurity trends.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →